Welcome to our dedicated page for Novartis SEC filings (Ticker: NVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novartis AG (NVS) SEC filings page on Stock Titan provides access to the company’s US regulatory disclosures, including Form 20‑F annual reports and Form 6‑K current reports. As a foreign private issuer based in Basel, Switzerland, Novartis uses these filings to communicate with US investors about financial performance, capital markets activity, clinical and regulatory milestones, and strategic transactions.
Form 6‑K reports frequently incorporate press releases on key events such as US Food and Drug Administration (FDA) approvals, major trial readouts and business development deals. Recent 6‑K filings have included announcements of FDA approvals for Rhapsido (remibrutinib) in chronic spontaneous urticaria, Vanrafia (atrasentan) for reduction of proteinuria in primary IgA nephropathy, Fabhalta (iptacopan) for C3 glomerulopathy, Leqvio (inclisiran) label expansion for hypercholesterolemia, and Itvisma (onasemnogene abeparvovec‑brve) for spinal muscular atrophy in older children, teens and adults. Other 6‑K filings detail positive Phase III results for ianalumab in Sjögren’s disease, multi‑asset collaborations, and the planned acquisition of Avidity Biosciences.
Investors can also find financial information in Novartis filings, such as quarterly financial reports, constant‑currency sales guidance and core operating margin disclosures. Certain 6‑K filings cover debt offerings by Novartis Capital Corporation, including terms agreements and forms of guaranteed debt securities for various note maturities, which are incorporated into the company’s shelf registration statements.
Stock Titan enhances these filings with AI‑powered summaries that explain the significance of each document in clear language. Users can quickly understand how a new 6‑K about a clinical trial result, an FDA decision, or a strategic acquisition may relate to Novartis’s pipeline and growth outlook. The filings page updates as new documents are posted to EDGAR, helping users follow NVS regulatory communications in near real time. While insider transaction details for Novartis are reported under applicable rules, this page focuses on the company’s primary SEC submissions, including 20‑F annual reports, 6‑K current reports, and related exhibits.
Novartis AG filed a Form 6-K to incorporate documents related to a large multi-tranche U.S. dollar notes issuance by Novartis Capital Corporation into its existing Form F-3 shelf registration.
The filing covers a $500,000,000 Floating Rate Notes issue due 2029 and six series of fixed-rate notes: $1,250,000,000 of 4.100% Notes due 2029, $1,750,000,000 of 4.400% Notes due 2031, $2,000,000,000 of 4.600% Notes due 2033, $2,250,000,000 of 4.900% Notes due 2036, $1,000,000,000 of 5.600% Notes due 2046, and $2,250,000,000 of 5.700% Notes due 2056.
The exhibits include the terms agreement with a syndicate of underwriters, forms of guaranteed debt securities for each series, an officer’s certificate, and legal opinions and consents from U.S. and Swiss counsel.
Novartis AG is offering an aggregate of $11,000,000,000 in notes, fully and unconditionally guaranteed by Novartis AG.
The offering comprises seven series: $500,000,000 floating rate notes due March 16, 2029 (Compounded SOFR + 0.650%) and six fixed-rate series totaling $10,500,000,000 with coupons from 4.100% to 5.700% and maturities from 2029 through 2056. Net proceeds of approximately $10,910.7 million are intended for general corporate purposes, including repayment of the Avidity Bridge Loan.
Novartis Capital Corporation proposes an offering of multiple series of senior notes, including floating rate notes tied to Compounded SOFR and several fixed rate notes maturing between 2029 and 2056, each fully and unconditionally guaranteed by Novartis AG. The offering contemplates book-entry issuance in minimum denominations of $2,000 and includes optional redemption provisions, tax‑related redemption rights, and benchmark transition mechanics for the SOFR‑linked notes. The net proceeds are intended for general corporate purposes outside Switzerland, including repayment of the Avidity Bridge Loan financing the Avidity Biosciences acquisition.
The prospectus supplement discloses that Novartis AG reported $54.5 billion in net sales and $14.0 billion net income from continuing operations for 2025, and that Novartis Capital Corporation is a wholly owned indirect subsidiary of Novartis AG established to issue debt and provide proceeds to affiliates.
A holder of the issuer’s American Depositary Shares has filed a notice of planned resale under Rule 144. The filing covers 30,743 American Depositary Shares, with an aggregate market value of 4,960,276.69, to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/12/2026. These shares were acquired on 01/29/2026 via restricted stock vesting as compensation from the issuer. The filing notes that shares of the same class outstanding total 1,908,151,679.
An affiliate of the issuer has filed a notice of proposed sale covering 7500 American Depositary Shares, to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/09/2026 and an aggregate market value of 1171575.75.
The securities relate to a larger base of 1908151679 shares outstanding. The 7500 shares were acquired on 01/29/2026 via restricted stock vesting from the issuer as compensation, and this notice confirms the holder’s representation that they are not aware of undisclosed material adverse information about the issuer.
Novartis furnished a report on Form 6-K that provides investors with access to its latest annual information. The filing submits the Novartis Annual Report 2025 and the Report on Nonfinancial Matters 2025 as exhibits, making these documents officially available under U.S. securities law for foreign private issuers.
Novartis reported solid 2025 results with higher sales, profits and cash generation. Full‑year net sales reached USD 54.5 billion, up 8% at constant currencies, driven by strong volume growth partly offset by generic competition and pricing pressure.
Profitability improved meaningfully. Operating income rose to USD 17.6 billion (up 21%), while core operating income increased to USD 21.9 billion, lifting the core margin to 40.1% of net sales. Free cash flow was USD 17.6 billion, up 8%.
Key growth brands such as Kisqali, Kesimpta, Pluvicto, Cosentyx and Scemblix delivered strong double‑digit growth, and the pipeline advanced with new approvals and positive Phase III results in oncology, immunology and rare diseases. The Board proposes a dividend of CHF 3.70 per share, a 5.7% increase, and continued large share repurchases reduced shares outstanding by 66.9 million, contributing to a 22% rise in EPS to USD 7.21.
Novartis AG files its Form 20-F annual report describing its global pharmaceuticals business, 2025 performance context, and extensive risk profile. The company reports using IFRS in US dollars and had 1 908 151 679 ordinary shares outstanding as of year-end.
The report highlights strategic risks from global pricing and reimbursement pressure, including US measures such as the Inflation Reduction Act and “maximum fair price” agreements, and notes the loss of US exclusivity for Entresto in July 2025. It stresses dependence on successful R&D, protection of intellectual property, and competitive product launches.
Novartis discusses recent acquisitions (including Anthos Therapeutics, Regulus Therapeutics and Tourmaline Bio) and integration risks, as well as challenges in implementing AI, major IT programs, and managing cybersecurity, data privacy and complex supply chains. The company discloses USD 27.9 billion of non-current financial debt and USD 5.6 billion of current financial debt, and outlines exposure to geopolitical, macroeconomic, climate, tax and regulatory changes.
Novartis AG has filed proxy-related materials describing its proposed acquisition of Avidity Biosciences, Inc. through a merger in which Novartis would indirectly acquire all outstanding Avidity shares. The transaction is linked to a planned spin-off or sale of Atrium Therapeutics, Inc. (“SpinCo”) from Avidity.
Avidity will prepare and deliver a definitive proxy statement and proxy card to its stockholders in advance of a special meeting to vote on the transactions. The materials emphasize that stockholders should read the definitive proxy statement and related SEC filings because they will contain important information about the deals and the parties involved.
The communication explains that Novartis, Avidity, SpinCo and certain of their directors, officers and employees may be considered participants in the proxy solicitation, and refers investors to existing SEC filings for details on their interests. It also includes extensive forward-looking statements language, noting that completion of the transactions is subject to customary closing conditions, including regulatory approvals and approval by Avidity stockholders, and highlighting risks such as potential delays, higher-than-expected costs, competing offers, business disruption and possible stockholder litigation.